Impact Events
MoreDate | Lead Company |
Event | Type | Approval Change |
Approval Likelihood |
---|---|---|---|---|---|
4/8/21 | Eli Lilly (LLY) | Olumiant for COVID-19 Treatment | Subscribers Only | Subscribers Only | Subscribers Only |
4/8/21 | Merck (MRK) | Keytruda for Renal Cell Cancer (RCC) | Subscribers Only | Subscribers Only | Subscribers Only |
4/6/21 | AstraZeneca (AZN) | Roxadustat for Anemia Due to Chronic Renal Failure, Dialysis-Independent | Subscribers Only | Subscribers Only | Subscribers Only |
4/6/21 | Valneva (VLA) | VLA2001 for COVID-19 Prevention | Subscribers Only | Subscribers Only | Subscribers Only |
4/5/21 | ACADIA Pharmaceuticals (ACAD) | Nuplazid for Dementia | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range |
Lead Company |
Drug | Expected Catalyst |
---|---|---|---|
08/16/19 | Subscribers Only | Subscribers Only | Partnership - Acquisition Completion |
10/01/21 - 12/31/20 | Subscribers Only | Subscribers Only | Trial Data - Top-Line Results |
04/10/21 | Subscribers Only | Subscribers Only | Trial Data - Top-Line Results |
04/10/21 | Subscribers Only | Subscribers Only | Trial Data - Top-Line Results |
04/10/21 | Subscribers Only | Subscribers Only | Trial Data - Top-Line Results |